Pre- and postexposure protection against virulent anthrax infection in mice by humanized monoclonal antibodies to Bacillus anthracis capsule

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 2, 2011, Pages 739-744

  Chen, Zhaochun ^a   Schneerson, Rachel ^c   Lovchik, Julie ^d   Lyons, C Rick ^d   Zhao, Huaying ^a   Dai, Zhongdong ^c   Kubler Kielb, Joanna ^c   Leppla, Stephen H ^b   Purcell, Robert H ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^d UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G3 ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTHRAX; ANTIGEN BINDING; ARTICLE; BACILLUS ANTHRACIS; BACTERIAL SPORE; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BACTERICIDAL ACTIVITY; BAGG ALBINO MOUSE; BINDING AFFINITY; CONTROLLED STUDY; DRUG EFFICACY; IN VITRO STUDY; LD 50; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; PROVOCATION TEST;

AMINO ACID SEQUENCE; ANIMALS; ANTHRAX; ANTI-INFECTIVE AGENTS; ANTIBODIES, MONOCLONAL; BACILLUS ANTHRACIS; HUMANS; IMMUNOGLOBULIN G; KINETICS; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; PAN TROGLODYTES; PHAGOCYTOSIS; PROTEIN BINDING; SEQUENCE HOMOLOGY, AMINO ACID; SURFACE PLASMON RESONANCE;

BACILLUS ANTHRACIS; MUS; PAN;

EID: 79551679357     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1017677108     Document Type: Article

References (33)

1. Karginov VA, et al. (2004) Treatment of anthrax infection with combination of ciprofloxacin and antibodies to protective antigen of Bacillus anthracis. FEMS Immunol Med Microbiol 40:71-74.
2. Turnbull PC, et al. (2004) MICs of selected antibiotics for Bacillus anthracis, Bacillus cereus, Bacillus thuringiensis, and Bacillus mycoides from a range of clinical and environmental sources as determined by the Etest. J Clin Microbiol 42:3626-3634.
3. Candela T, Mock M, Fouet A (2005) CapE, a 47-amino-acid peptide, is necessary for Bacillus anthracis polyglutamate capsule synthesis. J Bacteriol 187:7765-7772.
4. Green BD, Battisti L, Koehler TM, Thorne CB, Ivins BE (1985) Demonstration of a capsule plasmid in Bacillus anthracis. Infect Immun 49:291-297.
5. Makino S, Uchida I, Terakado N, Sasakawa C, Yoshikawa M (1989) Molecular characterization and protein analysis of the cap region, which is essential for encapsulation in Bacillus anthracis. J Bacteriol 171:722-730. (Pubitemid 19053478)
6. Uchida I, et al. (1993) Identification of a novel gene, dep, associated with depolymerization of the capsular polymer in Bacillus anthracis. Mol Microbiol 9: 487-496. (Pubitemid 23248761)
7. Drysdale M, et al. (2005) Capsule synthesis by Bacillus anthracis is required for dissemination in murine inhalation anthrax. EMBO J 24:221-227. (Pubitemid 40188479)
8. Ivins BE, et al. (1986) Immunization studies with attenuated strains of Bacillus anthracis. Infect Immun 52:454-458. (Pubitemid 16117800)
9. Welkos SL (1991) Plasmid-associated virulence factors of non-toxigenic (pX01-) Bacillus anthracis. Microb Pathog 10:183-198.
10. Turnbull PC (1991) Anthrax vaccines: Past, present and future. Vaccine 9:533-539.
11. Smith H, Keppie J, Stanley JL (1953) The chemical basis of the virulence of Bacillus anthracis. I. Properties of bacteria grown in vivo and preparation of extracts. Br J Exp Pathol 34:477-485.
12. Keppie J, Harris-Smith PW, Smith H (1963) The Chemical Basis of the Virulence of Bacillus Anthracis. Ix. Its Aggressins and Their Mode of Action. Br J Exp Pathol 44: 446-453.
13. Scorpio A, et al. (2007) Poly-gamma-glutamate capsule-degrading enzyme treatment enhances phagocytosis and killing of encapsulated Bacillus anthracis. Antimicrob Agents Chemother 51:215-222.
14. Schneerson R, et al. (2003) Poly(gamma-D-glutamic acid) protein conjugates induce IgG antibodies in mice to the capsule of Bacillus anthracis: A potential addition to the anthrax vaccine. Proc Natl Acad Sci USA 100:8945-8950.
15. Rhie GE, et al. (2003) A dually active anthrax vaccine that confers protection against both bacilli and toxins. Proc Natl Acad Sci USA 100:10925-10930.
16. Chabot DJ, et al. (2004) Anthrax capsule vaccine protects against experimental infection. Vaccine 23:43-47.
17. Wang TT, Fellows PF, Leighton TJ, Lucas AH (2004) Induction of opsonic antibodies to the gamma-D-glutamic acid capsule of Bacillus anthracis by immunization with a synthetic peptide-carrier protein conjugate. FEMS Immunol Med Microbiol 40:231-237.
18. Joyce J, et al. (2006) Immunogenicity and protective efficacy of Bacillus anthracis polygamma-D-glutamic acid capsule covalently coupled to a protein carrier using a novel triazine-based conjugation strategy. J Biol Chem 281:4831-4843.
19. Kozel TR, et al. (2004) mAbs to Bacillus anthracis capsular antigen for immunoprotection in anthrax and detection of antigenemia. Proc Natl Acad Sci USA 101:5042-5047.
20. Kozel TR, et al. (2007) Protective and immunochemical activities of monoclonal antibodies reactive with the Bacillus anthracis polypeptide capsule. Infect Immun 75: 152-163.
21. Wang TT, Lucas AH (2004) The capsule of Bacillus anthracis behaves as a thymusindependent type 2 antigen. Infect Immun 72:5460-5463.
22. Pain RH (2005) Determining the fluorescence spectrum of a protein. Current Protocols in Protein Science, eds Coligan JE, et al. (John Wiley & Sons Inc., New York), pp 7.7.1-7.7.20.
23. Lyons CR, et al. (2004) Murine model of pulmonary anthrax: Kinetics of dissemination, histopathology, and mouse strain susceptibility. Infect Immun 72:4801-4809.
24. Robbins JB, Schneerson R, Szu SC (1995) Perspective: Hypothesis: Serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum. J Infect Dis 171:1387-1398.
25. Ezzell JW, et al. (2009) Association of Bacillus anthracis capsule with lethal toxin during experimental infection. Infect Immun 77:749-755.
26. Chen Z, et al. (2006) Efficient neutralization of anthrax toxin by chimpanzee monoclonal antibodies against protective antigen. J Infect Dis 193:625-633. (Pubitemid 43271496)
27. Chen Z, et al. (2009) Novel chimpanzee/human monoclonal antibodies that neutralize anthrax lethal factor, and evidence for possible synergy with anti-protective antigen antibody. Infect Immun 77:3902-3908.
28. Chen Z, et al. (2009) Potent neutralization of anthrax edema toxin by a humanized monoclonal antibody that competes with calmodulin for edema factor binding. Proc Natl Acad Sci USA 106:13487-13492.
29. Chen Z, et al. (2006) Chimpanzee/human mAbs to vaccinia virus B5 protein neutralize vaccinia and smallpox viruses and protect mice against vaccinia virus. Proc Natl Acad Sci USA 103:1882-1887.
30. Chen Z, et al. (2007) Characterization of chimpanzee/human monoclonal antibodies to vaccinia virus A33 glycoprotein and its variola virus homolog in vitro and in a vaccinia virus mouse protection model. J Virol 81:8989-8995.
31. Schuck P, Boyd LF, Andersen PS (1999) Measuring protein interactions by optical biosensors. Current Protocols in Protein Science, eds Coligan JE, Dunn BM, Ploegh HL, Speicher DW, Wingfield PT (John Wiley & Sons, New York), pp 20.2.1-20.2.21.
32. Reed LJ, Muench H (1938) A simple method of estimating fifty percent endpoints. Am J Hyg 27:493-497.
33. Heninger S, et al. (2006) Toxin-deficient mutants of Bacillus anthracis are lethal in a murine model for pulmonary anthrax. Infect Immun 74:6067-6074. (Pubitemid 44657384)